Variation in Electrode Configuration for Termination of Out of Hospital Rhythms that are Shockable (VECTORS) Trial

What is the VECTORS trial?

The Variation in Electrode Configuration for Termination of Out‑of‑Hospital Rhythms that are Shockable (VECTORS) Trial is an emergency medicine study comparing anterior-posterior (AP) and anterior-lateral (AL) defibrillator electrode pad placement by emergency medical services (EMS) during treatment of out-of-hospital cardiac arrest (OHCA). Current guidelines from the American Heart Association (AHA) and International Liaison Committee on Resuscitation (ILCOR) recommend an AL-first or AP-first defibrillation strategy, favoring AL-first. Recent studies have demonstrated an association between AP-first placement and higher odds of return of spontaneous circulation (when the heart maintains a perfusing heart rhythm after a cardiac arrest) for patients with a shockable rhythm (ventricular fibrillation or pulseless ventricular tachycardia) as compared to AL-first placement. VECTORS is a trial to compare the impact of AP-first versus AL-first pad placement for OHCA on patient outcomes. The goal of this trial is to test if one pad position is superior to the other and results in better patient outcomes.

What is cardiac arrest and how is it treated?

Cardiac arrest is the loss of detectable pulses and can be caused by a primary electrical malfunction (ventricular fibrillation or ventricular tachycardia) or be due to other causes. Overall, survival from cardiac arrest nationally is near 10%. For cardiac arrest due to electrical abnormalities in the heart, the heart does not beat normally and a patient is without pulses. In addition to cardiopulmonary resuscitation, rapid defibrillation – a shock from a defibrillator – can restore normal electrical function and as a result, a pulse. Successful defibrillation depends on a sufficient electrical current passing through the heart to restore normal electrical function and a pulse. Current guidelines by the AHA and ILCOR recommend defibrillator pads be placed AL-first or AP-first, but favor AL-first placement. 

What is the study population?

The VECTORS study will be conducted across multiple counties in Oregon and Southwest Washington including Clark and Skamania in Washington and Washington, Yamhill, Multnomah, Clackamas, Lane, Marion, Polk, and Deschutes counties. The study will enroll adults who have cardiac arrest with a rhythm of ventricular fibrillation or ventricular tachycardia (shockable rhythms) during EMS resuscitation. Participating EMS agencies will alternate pad placement during treatment of OHCA between AP and AL on a set calendar basis (e.g. monthly or quarterly).  No further care is changed or dictated, whether by EMS or in the hospital, by the study.

Frequently Asked Questions

Why is this study being done?

To determine the best pad placement position – anterior-posterior or anterior-lateral – for cardiac arrest.

How long is this study ongoing?

The study aims to enroll patients over the course of 36 months.

What are the risks of the study?

Participation in the study involves two groups each receiving care considered standard of practice (AL-first or AP-first pad placement are both equal strategies per the American Heart Association). There is a risk that due to one placement or another patients may receive more (or less) effective shocks, but currently this is not known to be true. There is also a risk that one position causes delays to other care.

Will this study impact any other parts of patient treatment?

No, the only part of this study that changes usual treatment is the initial placement of defibrillator electrode pads (AP vs AL) during resuscitation of OHCA. No further EMS or in-hospital care is modified by this study. 

Exception from Informed Consent

Ethical standards require that researchers get permission before a person can be included in a study through a process called informed consent. However, cardiac arrest is an emergency condition that must be treated immediately. There will not be enough time to locate and talk to the person’s family, guardian, or legal representative about the study. Patients enrolled in VECTORS will be enrolled before permission can be given. This is called “Exception from Informed Consent” (EFIC). Patients and/or the legal representative of patient’s enrolled in this study will be notified about enrollment as soon as possible.

What is Exception From Informed Consent (EFIC)?

The U.S. Food and Drug Administration (FDA) is an agency of the federal government that oversees human research protection involving medicines. The FDA has created a set of special rules, called Exception from Informed Consent (EFIC), for clinical trials that apply to critically ill patients who require emergency treatment when obtaining consent in advance is not possible or may put the patient at risk for increased harm by delaying potentially life-saving therapies. Under some circumstances, there may not be time to obtain consent in advance from every eligible patient. In some cases, such as cardiac arrest, discussing a possible option to enroll in a study with family may cause dangerous delays in a person’s care. Nonetheless, many critically ill patients could benefit from enrollment in an appropriate clinical trial. Therefore, to ensure that clinical trials can be conducted for patients in emergencies, the FDA established rules for EFIC that require special safeguards to ensure that most people would consider the study ethical and appropriate. These special rules allow research studies in certain emergencies to be conducted without obtaining consent in advance.

EFIC can only be used when:

  • The person’s life is at risk, AND
  • The best treatment is not known, AND
  • The study might help the person, AND
  • It is not possible to get permission:
    • From the person because of their medical condition NOR
    • From the person’s guardian, because there is a very short amount of time required to treat the medical problem

Before researchers start a study using EFIC, they must provide information about the study to the community and get their feedback.

For Medical Professionals

This trial will compare the impact of anterior-posterior (AP) compared to anterior-lateral (AL) pad placement for out-of-hospital cardiac arrest on patient outcomes. Currently, international guidelines recommend either AP or AL or favor AL pad placement. A 2022 clinical trial evaluating vector change for shock-refractory ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT) found switching from AL to AP at the fourth shock resulted in higher termination of VF and survival to hospital discharge. Our research found associations between initial AP pad placement, as opposed to AL, and higher return of spontaneous circulation (ROSC) for patients presenting with VF/pVT cardiac arrest or non-shockable initial rhythms later transitioning to VF/pVT. This study will evaluate the effectiveness of initial AP vs AL pad placement to determine the optimal pad placement for defibrillation for patients suffering from cardiac arrest. This study will be conducted in the Portland, Oregon metropolitan region by participating emergency medical services (EMS) agencies. The study is funded by the American Heart Association.

To be eligible for enrollment in the study, patients must meet the following general enrollment criteria:

  • Emergency medical services (EMS)-treated non-traumatic out-of-hospital cardiac arrest

Exclusion criteria are:

  • ROSC at EMS arrival (e.g., bystander defibrillator shock with ROSC prior to EMS care) without rearrest during EMS care
  • Known prisoners
  • Known pregnant patients
  • Known pediatric patients (treated under the pediatric algorithm, generally <15 years)
  • Known preexisting do-not-resuscitate orders limiting care

Because cardiac arrest is a medical emergency and requires immediate treatment, it will not be possible to obtain informed consent from patients before they are enrolled. Therefore, eligible patients will be enrolled under the U.S. Food and Drug Administration’s exception from informed consent (EFIC) requirements for emergency research (21 CFR 50.24). These special rules allow research studies in certain emergency situations to be conducted without consent. EFIC can be used only when the person’s life is at risk, the best treatment is not known (in this instance, the optimal initial pad placement), the study might help the person, and it is not possible to obtain informed consent from the patient or a legally authorized representative prior to treatment. EFIC has been used for other EMS-based studies in Oregon and nationally in both children and adults.

In the study participating agencies will alternate pad placement between AP and AL (crossover) on a set calendar bases (e.g. monthly or quarterly).  Paramedics will receive training about these changes before the study protocol is implemented. The study does not dictate or change any in-hospital care of patients.